Position in AKBA
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$41,467
-$33,720 QoQ
Shares Held
29,833
-36.1% QoQ
Ownership
0.011%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2024
8 quarters on record
Voting authority
Sole 71%
Shared 0%
None 29%
Common Shares in AKBA Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Mar 31, 2026Focus Partners Wealth holds $54,434,760 across 17 Drug Manufacturers - Specialty & Generic names. AKBA ranks #16 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ZTS |
Zoetis Inc.
|
137,784 | $16,287,446 | |
| 2 | NBIX |
Neurocrine Biosciences Inc
|
80,335 | $10,583,332 | |
| 3 | TAK |
Takeda Pharmaceutical Co Ltd
|
482,387 | $8,933,807 | |
| 4 | LNTH |
Lantheus Holdings, Inc.
|
72,517 | $5,500,414 | |
| 5 | UTHR |
UNITED THERAPEUTICS Corp
|
5,854 | $3,471,304 | |
| 6 | ALKS |
Alkermes plc.
|
77,052 | $2,724,558 | |
| 7 | HLN |
Haleon plc
|
195,548 | $1,957,435 | |
| 8 | VTRS |
Viatris Inc
|
132,034 | $1,783,779 |
All Filings in AKBA
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $41,467 | 29,833 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $75,187 | 46,700 | Shares | Sole | 2026-02-13 | |
| 2025-09-30 | $83,513 | 30,591 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $48,291 | 13,267 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $21,870 | 11,391 | Shares | Sole | 2025-05-20 | |
| 2024-12-31 | $20,694 | 10,892 | Shares | Sole | 2025-05-29 | |
| 2024-06-30 | $14 | 10,575 | Shares | Sole | 2024-08-15 | |
| 2024-03-31 | $13 | 10,538 | Shares | Sole | 2024-05-16 | |
| No filing history on record for this holder in this stock. | ||||||